Clinical comparison of ibutilide and propafenone for converting atrial flutter

Cardiovascular Drugs and Therapy

Volumn 19, Issue 1, 2005, Pages 57-64

  Sun, Jian Ling ^a   Guo, Ji Hong ^a   Zhang, Nan ^a   Zhang, Hai Cheng ^a   Zhang, Ping ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Arrhythmia; Atrial flutter; Conversion; Ibutilide; Propafenone; Tolerability

Indexed keywords

IBUTILIDE; PROPAFENONE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOTENSION; MALE; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FLUTTER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROPAFENONE; PROSPECTIVE STUDIES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044389715     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-6898-y     Document Type: Article

References (22)

1. Cheng J, Glatter K, Yang Y, et al. Electrophysiological response of the right atrium to ibutilide during typical flutter. Circulation 2002;106:814-819.
2. Crijns HJGM, Mooder JA, Van Golder IC, et al. Effects of aimokalant in atrial fibrillation and flutter. Eur Heart J 1994;15:1403-1408.
3. Ching-Tai Tai, Shih-Amm Chen, An-Ning Feng, et al. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: Insights into the mechanism of termination. Circulation 1998;97:1935-1945.
4. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78(8A):12-16.
5. Inoue H, Yamashita T, Nozaki A, Sugimoto T. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: Role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol 1991;18:1098-1104.
6. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31(6):1414-1419.
7. Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 1998;79:668-675.
8. Grant AO. Propafenone: An effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol 1996;7:353-364.
9. Duan D, Fermini B, Natter S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993;264:1113-1123.
10. Spinelli W, Hoffman BF. Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res 1989;65:1565-1579.
11. Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992;222:93-98.
12. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996;28(1):130-136.
13. Hongo EH, Themistoclakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004;44(4):864-868.
14. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94(7):1613-1621.
15. Sen L, Gui G, Sakaguchi Y, et al. Electrophysiological effects of MS-551, a new class III agent: Comparison with dl-sotalol in dogs. J Pharmacol Exp Ther 1998;285(2):687-694.
16. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993;22:540-549.
17. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy. Circulation 1997;96(12):4298-4306.
18. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994;331:31-38.
19. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM, and the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996;94:1996-2012.
20. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in anti-arrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82:2235-2242.
21. Crijns HJ, Kingma JH, Gosselink AT, et al. Comparison in the same patient of aberrant conduction and bundle branch reentry after dofetilide, a new selective class III antiarrhythmic agent. Pacing Clin Electrophysiol 1993;16(5 Pt 1):1006-1016.
22. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. Pacing Clin Electrophysiol 1998;21(5):1044-1057.